Abstract
This paper analyses the factors that determineentry into the Swedish pharmaceuticals market. The analysis is based onpanel data for 22 different substances covering the years 1972 to 1996. Theresults show that profit opportunities in a particular market have apositive impact on entry. In addition, there is some evidence suggestingthat the length of the patent protection period has a negative impact onentry.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Al-Osh, M. A., and A. A. Alzaid (1987) ‘First-Order Integer Valued Autoregressive (INAR(1)) Process’. Journal of Time Series Analysis, 8, 261–275.
Andersson, F., and P. Hertzman (1993) ‘Effective Patent Life of Drugs in Sweden — A Comparison with International Studies’, Managerial and Decision Economics, 14, 53–63.
Bae, J. P. (1997) ‘Drug Patent Expirations and the Speed of Generic Entry’, Health Services Research, 32, 87–101.
Berglund, E., and K. Brännäs (1996) ‘Entry and Exit of Plants: A Study Based on Swedish Panel Count Data’, Yearbook of the Finnish Statistical Society, 95–111.
Brännäs, K. (1995) Explanatory Variables in the AR(1) Poisson Model. Umeå Economic Studies, No. 381.
Brännäs, K., and J. Hellström (1998) Forecasting Based on Very Small Samples and Additional Non-Sample Information. Umeå Economic Studies, No. 472.
Brännäs, K., and J. Hellström (1999) Generalized Integer-Valued Autoregression. Umeå Economic Studies, No. 501.
Cameron, A. C., and P. Trivedi (1998) Regression Analysis of Count Data. Cambridge: Cambridge University Press.
Caves, R. E., M. D. Whinston, and M. A. Hurwitz (1991) Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry. Brookings Papers on Economic Activity: Microeconomics. Washington, DC: Brookings Institution.
Grabowski, H. G., and J. M. Vernon (1992) ‘Brand Loyalty, Entry and Price Competition in Pharmaceuticals after the 1984 Drug Act’, Journal of Law and Economics, 35, 331–350.
Greene, W. H. (1993) Econometric Analysis. New Jersey: Prentice-Hall.
Hudson, J. (1992) ‘Pricing Dynamics in the Pharmaceutical Industry’, Applied Economics, 24, 103–112.
Masson, A., and R. L. Steiner (1985) Generic Substitution and Prescription Drug Prices. Washington, DC: Federal Trade Commission.
McKenzie, E. (1985) ‘Some Simple Models for Discrete Variate Time Series’, Water Resources Bulletin, 21, 645–650.
Scott-Morton, F. M. (1999) ‘Entry Decisions in the Generic Pharmaceutical Industry’, RAND Journal of Economics, 30, 421–440.
Stigler, G. J. (1968) The Organization of Industry. Homewood: Richard D. Irwin, Inc.
White, H. (1980) ‘A Heteroskedasticity-Consistent Covariance Matrix Estimator and a Direct Test for Heteroskedasticity’, Econometrica, 48, 817–838.
Yu, S. S. (1984) ‘Some Determinants of Entry into Therapeutic Drug Markets’, Review of Industrial Organization, 1, 260–275.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rudholm, N. Entry and the Number of Firms in the Swedish Pharmaceuticals Market. Review of Industrial Organization 19, 351–364 (2001). https://doi.org/10.1023/A:1011868404205
Issue Date:
DOI: https://doi.org/10.1023/A:1011868404205